HOME >> MEDICINE >> NEWS
NIAID Ebola vaccine enters human trial

quency.

On November 17, 2003, the World Health Organization reported 11 cases of Ebola hemorrhagic fever in the Republic of the Congo. Dr. Nabel notes, "The current Ebola outbreak in the Congo provides a stark reminder of the need to rapidly develop vaccines against such perilous infections. A few years ago, we did not imagine that our vaccine would enter human trials so quickly, but the re-emergence of such viruses makes it all the more important to respond quickly. Individuals who volunteer for these vaccine trials can help us understand if our new vaccines ultimately will be effective."

Twenty-seven volunteers between the ages of 18 and 44 will participate in the study. Six people will receive a placebo injection and 21 will receive the investigational vaccine, manufactured by Vical Inc., a San Diego biotechnology company working in collaboration with the VRC. Vical has also secured a nonexclusive license from NIH to proprietary gene sequences used in the DNA Ebola vaccine. In the new trial, volunteers will receive three injections over two months and will be followed for one year. Volunteers will not be exposed to Ebola virus. Individuals interested in enrolling in the trial may visit http://www.clinicaltrials.gov or call the VRC toll-free at 1-866-833-LIFE (5433).

The candidate vaccine is synthesized using modified, inactivated genes from Ebola virus. This gives the immune system information about viral structures so that it can mount a rapid defense should the real virus ever be encountered. There is no infectious material in the vaccine, and the virus was not present during any stage of the manufacturing process, notes Barney Graham, M.D., Ph.D., director of the clinical trials unit of the VRC. "It is impossible for the vaccine to cause infection," he adds, "because it employs new technology known to safely stimulate broad immune responses."

Besides assessing the vaccine's safety, re
'"/>

Contact: Contact: Anne A. Oplinger
aoplinger@niaid.nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases
18-Nov-2003


Page: 1 2 3

Related medicine news :

1. NIAID initiates trial of experimental avian flu vaccine
2. NIAID seeks applicants to lead clinical trials units for revamped HIV/AIDS networks
3. NIAID begins enrolling volunteers for novel HIV vaccine study
4. NIAID-sponsored clinical trial aims to boost flu vaccine supply
5. NIAID seeks applicants to lead revamped HIV/AIDS clinical trials networks
6. NIAID launches influenza genome sequencing project
7. NIAID launches program to improve medical tools against emerging infectious diseases
8. NIAID forms network to tackle potentially fatal reaction to smallpox vaccine
9. NIAID rotavirus vaccine licensed for commercialization
10. Second NIAID SARS vaccine candidate helps mice fend off SARS
11. NIAID vaccine protects against SARS virus infection in mice

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: NIAID Ebola vaccine enters human trial

(Date:8/22/2014)... Newport Hospital has again attained the distinguished Magnet ... (ANCC) Magnet Recognition Program. Considered the gold standard ... recognizes nursing excellence and professionalism. It is the ... unanimous decision to redesignate Newport Hospital was based ... standards of nursing practice. , "It is a ...
(Date:8/22/2014)... August 22, 2014 Home Care ... in-home care for seniors, is proud to announce the ... The upcoming webinar will feature Dr. Suzanne Steinbaum, attending ... Hill Hospital in New York City, National Spokesperson for ... The webinar will cover the issues surrounding women and ...
(Date:8/22/2014)... FRIDAY, Aug. 22, 2014 (HealthDay News) -- Counseling may ... a large-scale review finds. Researchers analyzed 66 studies ... of whom were at high risk for drinking problems. ... session, while participants in the rest of the studies ... individual sessions. A counseling technique called motivational interviewing ...
(Date:8/22/2014)... Aug. 22, 2014 (HealthDay News) -- Inner city children have ... finds. Researchers followed 516 inner city children in four ... -- from birth until age 5 and found that at ... eggs or peanuts. Because only the three most common ... actual number of inner city youngsters with food allergies may ...
(Date:8/22/2014)... the previous few years, several breakthrough treatments have ... Patients who may benefit from these treatments can ... in their cancer. For example, patients whose lung ... ALK derive significant benefit from the drug crizotinib, ... are now attempting to replicate this success by ...
Breaking Medicine News(10 mins):Health News:Newport Hospital receives nursing's highest credential for third time with Magnet recognition 2Health News:Home Care Assistance of Centennial to Host Webinar on Heart Health, Featuring Dr. Suzanne Steinbaum 2Health News:Home Care Assistance of Centennial to Host Webinar on Heart Health, Featuring Dr. Suzanne Steinbaum 3Health News:Counseling Does Little to Deter Youth Drinking, Review Finds 2Health News:Food Allergies More Common Among Inner City Kids, Study Finds 2Health News:Online screening for rare lung cancer subtypes opens door to new kind of clinical trial 2Health News:Online screening for rare lung cancer subtypes opens door to new kind of clinical trial 3Health News:Online screening for rare lung cancer subtypes opens door to new kind of clinical trial 4
(Date:8/22/2014)... , Aug. 22, 2014 Research and ... Cell Research Products: Opportunities, Tools & Technologies" report ... supply stem cell research products or you wish to ... and lucrative this market is. The authors know you ... more effectively to scientists, to generate improved revenues and ...
(Date:8/22/2014)... Research and Markets has announced ... Catheter Industry Report 2014" report to their offering. ... Industry Report 2014 is a professional and in-depth study ... industry with a focus on the Chinese situation. ... including definitions, classifications, applications and industry chain structure. The ...
(Date:8/22/2014)... Cali ., Aug. 22, 2014  Research presented ... that a therapy being developed by Hera Therapeutics Inc. combats ... 70 percent of all cervical cancer. When tested ... of HPV-16, HPV-18 and HPV-11 cells, according to Louise ... who presented the findings at the Seattle ...
Breaking Medicine Technology:Global Stem Cell Research Products: Opportunities, Tools & Technologies - 2014 Report 2Global Stem Cell Research Products: Opportunities, Tools & Technologies - 2014 Report 3Global and Chinese Intravenous Catheter Industry Report 2014 2Study shows Hera Therapeutics experimental compound shuts down human papillomavirus that causes most cervical cancer 2
Cached News: